Point-of-care testing of methamphetamine and cocaine utilizing wearable sensors.
Anal Biochem
; 691: 115526, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38621604
ABSTRACT
The imperative for the point-of-care testing of methamphetamine and cocaine in drug abuse prevention necessitates innovative solutions. To address this need, we have introduced a multi-channel wearable sensor harnessing CRISPR/Cas12a system. A CRISPR/Cas12a based system, integrated with aptamers specific to methamphetamine and cocaine, has been engineered. These aptamers function as signal-mediated intermediaries, converting methamphetamine and cocaine into nucleic acid signals, subsequently generating single-stranded DNA to activate the Cas12 protein. Additionally, we have integrated a microfluidic system and magnetic separation technology into the CRISPR system, enabling rapid and precise detection of cocaine and methamphetamine. The proposed sensing platform demonstrated exceptional sensitivity, achieving a detection limit as low as 0.1 ng/mL. This sensor is expected to be used for on-site drug detection in the future.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cocaína
/
Testes Imediatos
/
Dispositivos Eletrônicos Vestíveis
/
Metanfetamina
Limite:
Humans
Idioma:
En
Revista:
Anal Biochem
Ano de publicação:
2024
Tipo de documento:
Article